Content

Tesamorelin Ipamorelin: Two Receptors, One Vial

Creator: Nadia Okonjo, Health Writer
Published: 2026-08-26

Two peptides, two pituitary receptors, one vial. Each half has a research record of its own; the combination has never been tested as a combination.

Nadia Okonjo, Health Writer August 26, 2026 7 min read

A man in a long-sleeve hiking shirt pauses on a wide woodland trail, looking toward the ridge

The short version

A tesamorelin ipamorelin blend pairs a GHRH analogue with a selective growth hormone secretagogue acting at the ghrelin receptor - two different receptors feeding one output.
No published clinical trial has tested the two together. Searched in August 2026, PubMed returns no trial of the pair and ClinicalTrials.gov lists no registered study combining them.
Tesamorelin's own record is specific: visceral fat fell 15.2% against a 5.0% rise on placebo over 26 weeks in 412 people with HIV-associated abdominal fat, with IGF-I up 81.0%.
Ipamorelin's distinguishing feature is selectivity - in swine, doses over 200-fold above the GH-releasing dose did not raise ACTH or cortisol - but its only registered human efficacy trial, in postoperative ileus, missed its endpoint.
The blend is prepared as a compounded medication, which is different from an FDA-approved product: the combination offered here is not FDA-approved.
Because the pair has no trial of its own, the clinical work is screening and IGF-1 monitoring, set by a prescriber rather than by a dosing chart from a seller.

A tesamorelin ipamorelin blend pairs two peptides that reach the pituitary through two different receptors. Tesamorelin is an analogue of growth-hormone-releasing hormone (GHRH); ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor instead. Each half has a research record of its own. The pair does not: no published clinical trial has tested tesamorelin together with ipamorelin. The case for combining them is pharmacological reasoning, not trial evidence, and that distinction is the honest centre of this page.

Why a tesamorelin ipamorelin blend exists at all

Growth hormone comes out in pulses, and the size of those pulses is set by two separate signals arriving at the same cells in the anterior pituitary.

The first is GHRH, which binds the GHRH receptor and tells somatotroph cells to release. The second runs through the growth hormone secretagogue receptor — the ghrelin receptor — a structurally different receptor with a different downstream pathway, which also acts on somatostatin, the braking signal that shuts a pulse down. Two receptors, two inputs, one output.

That the two inputs are independent is long-established pharmacology. In 18 healthy men given intravenous boluses, submaximal doses of a synthetic GH-releasing hexapeptide combined with GHRH produced GH release that was greater than either alone, and the investigators concluded the peptide and GHRH act through separate mechanisms (Bowers et al., J Clin Endocrinol Metab 1990). Read that study carefully, though: the molecules tested were a first-generation hexapeptide and native GHRH(1-44), given intravenously. They were not tesamorelin and ipamorelin.

What is known about tesamorelin on its own

Tesamorelin is GHRH(1-44) carrying a trans-3-hexenoyl group at the N-terminus, an addition that slows enzymatic breakdown enough to make daily subcutaneous dosing workable.

In a 26-week randomised trial of 412 people with HIV and accumulated abdominal fat, visceral adipose tissue fell 15.2% on tesamorelin 2 mg daily and rose 5.0% on placebo, and IGF-I rose 81.0% against a 5.0% fall; glycaemic measures did not differ significantly (Falutz et al., N Engl J Med 2007). A pooled analysis of the two phase 3 studies, 806 patients in total, reported a treatment effect of -15.4% on visceral fat at 26 weeks, maintained through 52 weeks in those who stayed on it (Falutz et al., J Clin Endocrinol Metab 2010). A later 12-month trial in 61 people with HIV and fatty liver reported a 37% relative reduction in hepatic fat fraction against placebo, with 35% versus 4% reaching a fat fraction below 5% (Stanley et al., Lancet HIV 2019).

Those are real numbers from real trials, and every one comes from people with HIV-associated fat accumulation rather than healthy adults using the compound for body composition. What tesamorelin does covers the mechanism in more depth, and tesamorelin dosage covers how the amount gets decided rather than copied.

What is known about ipamorelin on its own

Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed from a series that dropped the central dipeptide of an earlier GH-releasing peptide. Its distinguishing feature is selectivity. In swine, doses more than 200-fold above the ED50 for GH release did not raise ACTH or cortisol beyond what GHRH itself produced, and FSH, LH, prolactin and TSH were unchanged — where two older GH-releasing peptides tested alongside it did raise ACTH and cortisol (Raun et al., Eur J Endocrinol 1998). That selectivity is why ipamorelin, rather than an older secretagogue, is the one that turns up in blends.

Human pharmacokinetics come from a dose-escalation study in healthy male volunteers: dose-proportional exposure, a terminal half-life of about two hours, and a single episode of GH release peaking around 40 minutes after the infusion (Gobburu et al., Pharm Res 1999) — one pulse, then back to baseline.

The honest gap is efficacy: ipamorelin's registered human programme was not in growth hormone support at all, but in postoperative ileus. In a phase 2 trial of 114 evaluable bowel-resection patients, intravenous ipamorelin 0.03 mg/kg twice daily for up to seven days was well tolerated, but median time to a first tolerated meal was 25.3 hours against 32.6 on placebo, which did not reach significance, and no secondary endpoint separated either (Beck et al., Int J Colorectal Dis 2014). Ipamorelin benefits sets out what that evidence does and does not support.

The combination has not been studied as a combination

This is the part most pages about this blend skip, so it is worth being exact. Searched in August 2026, PubMed returns no clinical trial of tesamorelin given with ipamorelin. The few records naming both are narrative reviews, not studies of the pair. ClinicalTrials.gov lists three registered ipamorelin studies in total, none combining it with tesamorelin or any other GHRH analogue.

So the rationale for a tesamorelin ipamorelin stack rests on the receptor logic above plus the 1990s synergy work — different molecules, different doses, intravenous rather than subcutaneous, single administrations rather than months of daily use. That is a reasonable pharmacological argument, and it is not the same thing as evidence for this pairing.

What remains unknown: whether synergy holds at the amounts used in a compounded vial, how IGF-1 moves over months on the pair compared with either alone, and whether the tolerability of each component predicts the tolerability of both. A page presenting the blend as trial-proven is describing a study that does not exist.

Tesamorelin on its own carries the trial record above and is dispensed as a single-agent preparation, which is why some prescribers would rather start there and add nothing they cannot interpret.

Where the regulators sit

Two brand tesamorelin products hold a current US approval — EGRIFTA SV and EGRIFTA WR — for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Their labelling states plainly that the drug is not indicated for weight loss management, that long-term cardiovascular safety has not been established, that IGF-1 should be monitored, and that active malignancy and pregnancy are contraindications.

Ipamorelin sits differently. At the Pharmacy Compounding Advisory Committee meeting of 29 October 2024, members voted 0 in favour, 12 against, 1 abstaining on placing ipamorelin free base on the 503A bulk drug substances list, and the same on ipamorelin acetate, citing a lack of safety and efficacy information in the available data for the two uses reviewed. Committee votes are advice to the agency; rulemaking is a separate step and has not concluded.

Regulatory status is one input into a prescribing decision, not the whole of it — a licensed provider may still prescribe a compounded formulation where they judge it appropriate, and that decision is between you and your doctor.

The preparation dispensed here is not the branded drug. It is prepared as a compounded medication, which is different from an FDA-approved product: the tesamorelin and ipamorelin combination offered here is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality.

How a prescriber approaches the pairing

Because the pair has no trial of its own, the clinical work sits in screening and monitoring rather than in a protocol. Anything that raises growth hormone signalling raises IGF-1, so a personal history of cancer is a serious question and an active malignancy is a stop. Pituitary or hypothalamic disease matters, since both compounds work by asking a pituitary to do something. Pregnancy and breastfeeding rule it out. Glucose is worth a baseline, because growth hormone is a counter-regulatory hormone. Current medications matter, particularly anything already acting on the same axis.

IGF-1 is then the measurable signal, and a persistent elevation is a reason to stop rather than a sign of progress — which is why a prescriber, not a chart from a seller, sets the amount and the review interval. The hormone and organ health hub lists the other compounds that work on this axis.

At Promise, a licensed provider reviews every request and prescribes only where it is appropriate. Not everyone qualifies, and being declined is a real outcome of a real review.

Common questions

Is the tesamorelin and ipamorelin blend FDA-approved?

No. FDA-approved tesamorelin products exist for one specific HIV-related indication, but the tesamorelin and ipamorelin combination offered here is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe a compounded preparation where they judge it appropriate, and that decision is between you and your doctor.

Why are tesamorelin and ipamorelin combined?

Because they reach the pituitary through two different receptors. Tesamorelin acts at the GHRH receptor; ipamorelin acts at the growth hormone secretagogue receptor, which also influences somatostatin, the braking signal on a growth hormone pulse. Work in healthy men in 1990 showed a GH-releasing peptide and GHRH combine to release more growth hormone than either alone, which is the pharmacological argument for pairing the two classes.

Has the tesamorelin ipamorelin combination been tested in a clinical trial?

No published trial has tested them together. Searched in August 2026, PubMed returns no clinical study of tesamorelin given with ipamorelin, and ClinicalTrials.gov lists three registered ipamorelin studies in total, none of which combines it with a GHRH analogue. The rationale for the blend is receptor pharmacology carried over from other molecules, not evidence for this pair.

What is the difference between tesamorelin and ipamorelin?

Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone that clears within minutes and has been studied in HIV-associated abdominal fat and fatty liver. Ipamorelin is a five-amino-acid secretagogue acting at the ghrelin receptor, with a terminal half-life of about two hours in healthy volunteers and no approved product anywhere. They are different molecules acting on different receptors.

Is ipamorelin on the FDA's 503A bulk drug substances list?

It is not. At its meeting on 29 October 2024, the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against and 1 abstaining on adding ipamorelin free base, and identically on ipamorelin acetate, citing limited safety and efficacy data for the uses reviewed. Committee votes are advice; rulemaking is a separate step. A prescriber may still judge a compounded preparation appropriate.

What does a provider check before prescribing a tesamorelin ipamorelin blend?

Cancer history first, since raising growth hormone signalling raises IGF-1 and an active malignancy is a stop. Then pituitary or hypothalamic disease, pregnancy or breastfeeding, a baseline glucose, current medications acting on the same axis, and a baseline IGF-1 to monitor against. Persistent IGF-1 elevation is a reason to stop rather than a sign of progress.